Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 – Biogen

Written by

admin

in

  1. Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025  Biogen
  2. CTAD 2025: Lecanemab Boosts CSF Aβ Protofibrils, Confirming Target Engagement and Pharmacodynamic Effect  Patient Care Online
  3. New data confirm pharmacological effect of Leqembi, says Eisai  The Pharma Letter
  4. Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer’s Disease 2025 Conference  MarketScreener
  5. Lecanemab shows effect on Alzheimer’s biomarkers in new study  Investing.com

Continue Reading

More posts